<SEC-DOCUMENT>0001144204-16-081945.txt : 20160216
<SEC-HEADER>0001144204-16-081945.hdr.sgml : 20160215
<ACCEPTANCE-DATETIME>20160216070030
ACCESSION NUMBER:		0001144204-16-081945
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160216
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160216
DATE AS OF CHANGE:		20160216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36357
		FILM NUMBER:		161422827

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v431918_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>February 16, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;<IMG SRC="logo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No. 001-36357</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">Delaware</font></td>
    <TD STYLE="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">99-0370688</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">(State or other jurisdiction of incorporation)</font></td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font-size: 10pt">(IRS Employer Identification Number)</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>675 Arapeen Drive, Suite 202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Salt Lake City, Utah 84108</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(801) 994-7383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report: <B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 1in"><font style="font-size: 10pt"><b>Item&nbsp;7.01</b></font></td>
    <TD><font style="font-size: 10pt"><b>Regulation FD Disclosures</b></font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On February 16, 2016, Lipocine Inc. issued a press release announcing
results from the multi-dose pharmacokinetic study with LPCN 1107. The press release is filed as Exhibit 99.1 and is incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">Item 9.01</TD><TD>Financial Statements and Exhibits.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Exhibits</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed with this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 19%; border-bottom: Black 1pt solid; padding-bottom: 12pt; text-decoration: underline"><font style="font-size: 10pt"><u>Exhibit No.&#9;</u></font></td>
    <td style="width: 81%; border-bottom: Black 1pt solid; padding-bottom: 12pt; text-decoration: underline"><font style="font-size: 10pt"><u>Description</u></font></td></tr>
<tr style="vertical-align: top">
    <td style="padding-bottom: 12pt"><font style="font-size: 10pt">99.1</font></td>
    <td style="padding-bottom: 12pt"><font style="font-size: 10pt">Press Release Announcing the Results from the Multi-Dose Pharmacokinetic Study with LPCN 1107 </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 85.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 85.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <td colspan="2"><font style="font-size: 10pt">LIPOCINE INC.</font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 35%">&nbsp;</td>
    <TD STYLE="width: 10%">&nbsp;</td>
    <TD STYLE="width: 5%">&nbsp;</td>
    <TD STYLE="width: 45%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">Date:</font></td>
    <TD STYLE="border-bottom: Black 1pt solid"><font style="font-size: 10pt">February 16, 2016</font></td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">By:</font></td>
    <TD STYLE="border-bottom: Black 1pt solid"><font style="font-size: 10pt">/s/ Mahesh V. Patel</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">Mahesh V. Patel</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD><font style="font-size: 10pt">President and Chief Executive Officer</font></td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v431918_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="logo1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>For Immediate Release</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE REPORTS POSITIVE RESULTS OF
MULTI-DOSE PHARMACOKINETIC STUDY OF LPCN 1107</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOR THE PREVENTION OF PRETERM BIRTH IN
PREGNANT WOMEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Relevant hydroxyprogesterone caproate levels achieved following oral administration</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Amenable to dose adjustment while on therapy</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Well tolerated with no serious adverse events or adverse drug reactions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SALT LAKE CITY (February 16, 2016<I>) &ndash;</I></B><I>
</I>Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced top-line results from its
multi-dose pharmacokinetic (&ldquo;PK&rdquo;) dose finding clinical study of LPCN 1107, its oral hydroxyprogesterone caproate (&ldquo;HPC&rdquo;)
product candidate for the prevention of preterm birth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The study was an open-label, four-period, four-treatment, randomized,
single and multiple dose, PK study in pregnant women of three dose levels of LPCN 1107 and injectable HPC (Makena<SUP>&reg;</SUP>).
The study enrolled 12 healthy pregnant women (average age of 27 years) with a gestational age of approximately 16 to 19 weeks.
Subjects received three dose levels of LPCN 1107 (400 mg BID, 600 mg BID, or 800 mg BID) in a randomized, crossover manner during
the first three treatment periods and then received five weekly injections of HPC during the fourth treatment period. During each
of the LPCN 1107 treatment periods, subjects received a single dose of LPCN 1107 on Day 1 followed by twice daily administration
from Day 2 to Day 8. Following completion of the three LPCN&nbsp;1107 treatment periods and a washout period, all subjects received
five weekly injections of HPC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Average steady state HPC levels (C<SUB>avg</SUB>0-24) were comparable
or higher for all three LPCN 1107 doses than for injectable HPC. HPC levels as a function of daily dose were linear for the three
LPCN 1107 doses. Unlike the injectable HPC,<B> </B>steady state exposure was achieved for all three LPCN 1107 doses within seven
days. The approved HPC injectable product is a single fixed dose product that does not allow for dose adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A previous literature study of 250 mg injectable HPC in pregnant
women reported that the lowest preterm birth rates were seen when median HPC concentrations exceeded 6.4 ng/mL and that the plasma
concentrations of HPC ranged between 3.7 to 56 ng/mL with the injectable HPC.<SUP>1</SUP> With all three LPCN 1107 doses tested,
HPC exposure (C<SUB>avg</SUB>0-24) did not fall below 6.4 ng/ml in any study subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LPCN 1107 was well tolerated across the three dose levels. No
adverse drug reactions, serious adverse events, or deaths were reported during the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are pleased that the dose linearity and short duration
to steady state demonstrated in this study could potentially allow dose adjustments of LPCN 1107 during the course of therapy to
optimize the clinical outcome,&rdquo; said Dr. Mahesh Patel, President and CEO of Lipocine. &ldquo;Given these encouraging data,
we plan to request a meeting with the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) to obtain agreement on a Phase 3 development
plan.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About LPCN 1107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LPCN 1107 is a novel oral product candidate in development for
the prevention of preterm birth in women with singleton pregnancy. Potential benefits of Lipocine&rsquo;s oral product candidate
relative to current injectable products include: customized dosing for patients and the elimination of pain and site reactions
associated with weekly injections, elimination of weekly doctor visits or visits from the nurse, and elimination of interference/disruption
of personal, family or professional activities associated with weekly visits. LPCN 1107 has received orphan drug designation from
the U.S. Food and Drug Administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Lipocine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. LPCN 1021,
an oral testosterone replacement therapy product candidate, demonstrated positive efficacy and safety results in Phase 3 testing
and has a New Drug Application under review with the FDA. LPCN 1111, a next-generation oral testosterone replacement therapy product
with once daily dosing, is currently in Phase 2 testing. LPCN 1107, which has the potential to become the first oral hydroxyprogesterone
caproate product indicated for the prevention of recurrent preterm birth. For more information, please visit www.lipocine.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This release contains &ldquo;forward looking statements&rdquo;
that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements
that are not historical facts relating to Lipocine&rsquo;s common stock and preferred stock, the FDA review process relating to
our product candidates and the outcome of such process, clinical trials, the potential uses and benefits of our product candidates,
product development and commercialization efforts and the projected timing and outcome of regulatory filings and actions. Investors
are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks
related to our products, expected product benefits, clinical and regulatory expectations and plans, regulatory developments and
requirements, risks related to the FDA&rsquo;s review of our NDA for LPCN 1021, the receipt of regulatory approvals, the results
of clinical trials, patient acceptance of Lipocine&rsquo;s products, the manufacturing and commercialization of Lipocine&rsquo;s
products, the risks related to market conditions for Lipocine&rsquo;s common stock and other risks detailed in Lipocine&rsquo;s
filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be
obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements
contained in this release, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONTACTS: </B> &#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morgan Brown</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President &amp; Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (801) 994-7383</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: mb@lipocine.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Woolford</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (443) 213-0500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">john.woolford@westwicke.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Heather Anderson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Phone: (980) 938-0260</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">handerson@6degreespr.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"># # #</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP>Caritis SN, Venkataramanan R, Thom E, et al. Relationship
between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth. Am J Obstet Gynecol 2014;210(2):128.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0(# 2(  A$! Q$!_\0
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MV%[_ %/Y&L"&V^*?B(?:5FU*%&Y!\\6H_!05_E7<^ /AU:>'K2+4-2A2;5G
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M_P!&1U[S7S)X&\5IX/UN;4)+1KH26S0;%?9C+*V<X/\ =_6O0?\ A>5M_P!
M&7_P)'_Q- 'K5>&?&[_D9M/_ .O/_P!G:MG_ (7E;?\ 0!E_\"1_\36#\8YQ
M=:UI%P%VB73U?;G.,LQQ0!O?&7_D6=#_ .NA_P#0!7>>"?\ D1]$_P"O./\
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M1^&K'6]+0G4+=IUDA!P+J+SG)0_[0ZJ>Q^M:7P^N$N]&U"YC#!)=3N)%##!
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1**'*Z"%-1;:ZA1114FA__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
